IRIS
DE LUCA, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.029
EU - Europa 2.419
AS - Asia 1.998
SA - Sud America 190
AF - Africa 14
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 1
Totale 7.661
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.002
SG - Singapore 739
CN - Cina 701
UA - Ucraina 450
IE - Irlanda 435
GB - Regno Unito 349
TR - Turchia 342
SE - Svezia 281
DE - Germania 222
IT - Italia 212
FR - Francia 200
BR - Brasile 172
FI - Finlandia 125
IN - India 97
RU - Federazione Russa 76
VN - Vietnam 43
CA - Canada 22
CZ - Repubblica Ceca 16
HK - Hong Kong 14
PL - Polonia 12
BD - Bangladesh 10
IR - Iran 10
BE - Belgio 9
EU - Europa 9
ZA - Sudafrica 9
AR - Argentina 8
CH - Svizzera 6
IL - Israele 6
IQ - Iraq 6
AT - Austria 5
LT - Lituania 5
MX - Messico 5
GR - Grecia 4
JP - Giappone 4
KZ - Kazakistan 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
ES - Italia 3
RS - Serbia 3
UY - Uruguay 3
AZ - Azerbaigian 2
CL - Cile 2
EC - Ecuador 2
ID - Indonesia 2
MA - Marocco 2
NP - Nepal 2
PK - Pakistan 2
RO - Romania 2
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
CO - Colombia 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
IM - Isola di Man 1
JO - Giordania 1
KE - Kenya 1
KR - Corea 1
LB - Libano 1
NL - Olanda 1
PH - Filippine 1
SA - Arabia Saudita 1
SR - Suriname 1
TJ - Tagikistan 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.661
Salva come PNG Salva come JPEG
Città #
Singapore 586
Jacksonville 511
Chandler 508
Dublin 431
Southend 258
Izmir 192
Princeton 188
Beijing 160
Nanjing 151
Wilmington 128
Ashburn 121
The Dalles 100
Santa Clara 96
Cambridge 84
Dearborn 84
Munich 61
Tongling 59
Nanchang 58
Ann Arbor 51
Woodbridge 51
New York 49
Altamura 45
Los Angeles 36
Chieti 34
Dong Ket 33
Council Bluffs 31
Hefei 30
Jiaxing 29
Houston 26
Boardman 25
Shenyang 25
Helsinki 24
Norwalk 24
Tianjin 20
Grevenbroich 19
Kunming 19
Turku 18
São Paulo 17
Washington 17
Hebei 16
Frankfurt am Main 15
London 14
Dallas 13
Hong Kong 13
Brno 12
Changsha 12
Hangzhou 12
Leawood 12
San Mateo 12
Ardabil 10
Brooklyn 10
Nuremberg 10
Warsaw 10
Augusta 9
Cedar Knolls 9
Jinan 9
San Francisco 9
Torino 9
Toronto 9
Brussels 8
Guangzhou 8
Lanzhou 8
Pescara 8
Teramo 8
Campobasso 7
Monmouth Junction 7
Stockholm 7
Boston 6
Falls Church 6
Fribourg 6
Johannesburg 6
Montesilvano Marina 6
Ningbo 6
Ankara 5
Changchun 5
Chicago 5
Hanover 5
Joinville 5
Orange 5
Phoenix 5
Rio de Janeiro 5
Rome 5
Roubaix 5
Taizhou 5
Zhengzhou 5
Brasília 4
Charlotte 4
Ho Chi Minh City 4
Montreal 4
Olomouc 4
San Vito Chietino 4
Tashkent 4
Atlanta 3
Belgrade 3
Belo Horizonte 3
Borgomanero 3
Curitiba 3
Dhaka 3
Düsseldorf 3
Florence 3
Totale 4.833
Salva come PNG Salva come JPEG
Nome #
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 139
IL 13 in multiple sclerosis 136
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells 128
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 113
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 111
Increasing age at disability milestones among MS patients in the MSBase Registry 111
La funzione soppressoria è ridotta nella polineuropatia demielinizzante cronica infiammatoria (CIDP) 107
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 107
Anti-glycolipid and anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy 105
Rantes Levels and mRNA Expression in Relapsing-Remitting Multiple Sclerosis (RR-MS): Effect of interferon Beta 1b (IFNBeta 1b) Treatment 105
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 102
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 101
Dysimmune demyelinating polyneuropathies: expression of adhesion molecules in sural nerves and changes in cellular immunity (suppressor cell function and cytokine mRNA expression) induced by treatment (progetto presentato a Telethon) 100
Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis 100
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 99
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 99
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 99
Effect of TNF intraneural injection into the rat sciatic nerve 97
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 97
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. 96
Rantes and MCP-1 Secretion by Mononuclear Cells of Patients with Nultiple Sclerosis 95
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 95
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 95
Chemokine production by mononuclear cells from relapsing-remitting multiple sclerosis (RR-MS) patients 95
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 94
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 94
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 94
Effects of IL10 on recombinant interferon-beta1b stimulated suppressor cell function in MS and controls subjects 93
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 93
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 93
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 93
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. 93
Serum soluble adhesion molecules and proinflammatory cytokines are not increased in chronic inflammatory demyelinating polyneuropathy 92
Interferon beta1b: the Chieti experience 91
Interferon beta normalizes suppressor cell function in dysimmune neuropathies. 90
rlFN-beta-1B stimulated suppressor cell function in multiple sclerosis: effects of anti-IL-10 monoclonal antibody 89
Effect of rhTNF-alpha injection into rat sciatic nerve 89
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 89
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 88
Shared T Cell Receptor Usage of Cerebrospinal Fluid Cells in Familial Multiple Sclerosis da: X° National A.I.N.I. Congress Association Italiana Neuroimmunologia - Florence, Italy, November 15/16,1999 87
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 87
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 86
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 86
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 85
Nail loss after teriflunomide treatment: a new potential adverse event 85
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 84
JCV-Ab serostatus in MS patients treated with Natalizumab 84
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 84
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 83
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 82
Effect of rhTNF-a injection into rat sciatic nerve 81
CD1A and CD1E gene polymorphisms are associated withsusceptibility to multiple sclerosis 80
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 80
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 79
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 79
Livelli sierici e liquorali di IL13 nella Sclerosi Multipla 78
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 78
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 77
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 77
Mononeuropathy following subcutaneous interferon-β injection 76
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 76
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 75
IL-13 levels in serum and cerebro-spinal fluid of multiple sclerosis patients 74
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 74
Interferon β 1b: The Chieti experience 73
Interferone beta1b: bilancio su un gruppo di 30 pazienti 72
Suppressor cell function is decreased in chronic inflammatory demyelinating polyneuropathy 72
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 72
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 71
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. 70
Evaluation of suppressor cell function in chronicn inflammatory demyelinating polyneuropathy (CIDP) 67
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 67
Effects of IFN-Beta on rantes and MCP-1 secretion by mononuclear cells frm patients with multiple sclerosis 66
Non-neuronal acetylcholine: a new modulator of immune responses in multiple sclerosis patients. 65
Epilepsy and multiple sclerosis: Clinical, radiological, electrophysiological and neuropsychological aspects 64
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 64
A Multicentre italian study on efficacy and safety of Glatiramer Acetate in multiple sclerosis patients with allergic respiratory diseases 64
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. 61
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla 60
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 59
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 58
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 57
Pregnancy and fetal outcomes after paternal exposure to disease modifying drugs for multiple sclerosis 57
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases 55
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 54
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 53
Modulation of the immune response in multiple sclerosis patients: effect of non-neuronal acetylcholine 49
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 49
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 47
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 47
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergicrespiratory diseases. 45
Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) 45
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 42
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 40
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose 38
Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge 34
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 29
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 8
Totale 7.798
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.200
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.200
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021530 0 0 91 1 37 123 1 2 80 68 58 69
2021/2022357 2 4 6 57 11 11 16 34 32 7 54 123
2022/20231.321 104 152 72 158 143 272 81 93 171 17 29 29
2023/2024653 46 30 38 16 37 225 145 30 0 31 5 50
2024/20251.766 117 317 334 26 34 65 42 59 123 94 230 325
2025/2026398 334 64 0 0 0 0 0 0 0 0 0 0
Totale 7.798